‘’Adverse impact of DPCO will be significant on OPPI member companies’’

Immediate adverse impact of DPCO 2013, on both sales and margins, will be quite significant to OPPI member companies. However, a change from cost-based to market-based pricing methodology is expected to have transparency and be directionally more prudent for the pharma industry on a longer term perspective.

– Tapan Ray, Director General, Organisation of Pharmaceutical Producers Of India (OPPI)